Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs

Executive Summary

Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.

You may also be interested in...



Helsinn And AB Science Persevere In EU Despite CHMP Setback

Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.

New Treatments For Psoriasis, Ovarian Cancer And MS Seeking CHMP Thumbs Up This Week

Fourteen medicines that are in the final stages of the evaluation process at the European Medicines Agency should find out this week whether they will be approved for marketing across the EU.

XBiotech Faces Uphill Task With Xilonix

Texas-based biotech XBiotech is going to find it tough to persuade clinicians and regulators about the usefulness of it its human antibody Xilonix after it discontinued the second Phase III study of the human antibody, in US colorectal cancer patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS121703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel